140 189

Cited 4 times in

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer

Authors
 Sara M Tolaney  ;  Joon Jeong  ;  Hao Guo  ;  Jane Brock  ;  Daniel Morganstern  ;  Steven E Come  ;  Mehra Golshan  ;  Jennifer Bellon  ;  Eric P Winer  ;  Ian E Krop 
Citation
 CANCER MEDICINE, Vol.3(2) : 293-299, 2014 
Journal Title
 CANCER MEDICINE 
Issue Date
2014
MeSH
Administration, Oral ; Adult ; Aged ; Antimetabolites, Antineoplastic/administration & dosage* ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/metabolism ; Breast Neoplasms/surgery ; Capecitabine ; Chemotherapy, Adjuvant ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives* ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives* ; Humans ; Middle Aged ; Neoplasms, Hormone-Dependent/drug therapy ; Neoplasms, Hormone-Dependent/metabolism ; Neoplasms, Hormone-Dependent/surgery ; Preoperative Care/methods ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism
Keywords
Breast ; cancer ; capecitabine ; chemotherapy ; preoperative
Abstract
Conventional preoperative chemotherapy regimens have only limited efficacy in hormone receptor positive (HR+) breast cancer and new approaches are needed. We hypothesized that capecitabine, which is effective in metastatic breast cancer, may be an active preoperative treatment for HR+ breast cancer. Women with HR+, HER2-negative operable breast cancer received capecitabine, 2000 mg/m2 daily in divided doses for 14 days, followed by a 7-day rest period. Treatment was repeated every 21 days for a total of four cycles. The primary endpoint of the study was to determine the rate of pathological complete response (pCR). Because of slow accrual, the study was closed after 24 patients were enrolled. Three patients had a complete clinical response, and eight patients had a partial clinical response, for an overall clinical response rate of 45.8%. There were no cases of pCR. Of the 22 patients who had pathological response assessment by the Miller–Payne grading system, there were six grade 3 responses, and no grade 4 or 5 responses. Toxicity was manageable: the only grade 3 toxicities observed were one case each of diarrhea, palmar plantar erythrodysesthesia, hypokalemia, and mucositis. There was no association between baseline levels, or change in level from baseline to cycle 1, or from baseline to time of surgery, of thymidine phosphorylase (TYMP), thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD), or Ki67 and pathological, clinical, or radiographic response. Preoperative capecitabine is a well-tolerated regimen, but appears not lead to pCR when used as monotherapy in HR+ breast cancer.
Files in This Item:
T201401339.pdf Download
DOI
10.1002/cam4.164
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/98702
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links